Second-line Anti-Tuberculosis Drugs and Risk of Alopecia: A Retrospective Cohort study

Mulugeta Russom, A. Berhe, L. Hagos
{"title":"Second-line Anti-Tuberculosis Drugs and Risk of Alopecia: A Retrospective Cohort study","authors":"Mulugeta Russom, A. Berhe, L. Hagos","doi":"10.4172/2167-1052.1000223","DOIUrl":null,"url":null,"abstract":"Background  \n \nAlopecia is not a well-known adverse effect of second-line anti-tuberculosis drugs. It is however, been frequently reported in Eritrea and 83% of the reports of alopecia associated with second-line anti-TB drugs in the global adverse drug reaction database, as of July 25, 2017, were submitted from Eritrea. It is wondering why this much variation is happening and this study is therefore aimed at quantifying the risk, identifying possible risk factors and elucidating the causal association between alopecia and the second-line anti-TB drugs in Eritrea. \n \nMethods \n \nThis was a retrospective cohort study that included all patients with multi-drug resistant tuberculosis (MDR-TB) in Eritrea enrolled to Merhano MDR-TB referral hospital for treatment between June 2011 and December 2016. \n \nResults \n \nA total of 152 eligible MDR-TB patients on treatment were identified with a median observation time of 23 months. Historical longitudinal data of these patients was screened and found 35 cases of alopecia, possibly associated with MDR-TB treatment, with an incidence rate of about 13 cases per 1000 person-months. Majority of the cases (68.6%) developed alopecia after 18 months of exposure to MDR-TB treatment. Patients exposed to treatment for longer period of time (>23 months) were more likely to develop alopecia compared to those exposed for shorter time (p=0.001). Patients younger than 45 years of age reported higher rates of alopecia compared to the older age groups (adjusted OR=9.4; 95%CI: 2.41-36.86, p=0.001). Females were also more likely to develop alopecia compared to males (adjusted OR=3; 95%CI: 1.24 - 7.34, p=0.015). \n \nConclusion \n \nAlopecia associated with MDR-TB treatment is frequent but its delayed time to onset might be a reason to be missed by several similar studies conducted elsewhere. Even though alopecia is not life-threatening and does not cause physical pain, the cosmetic effects of hair loss can be psychologically devastating.","PeriodicalId":7385,"journal":{"name":"Advances in Pharmacoepidemiology and Drug Safety","volume":"49 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacoepidemiology and Drug Safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2167-1052.1000223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background  Alopecia is not a well-known adverse effect of second-line anti-tuberculosis drugs. It is however, been frequently reported in Eritrea and 83% of the reports of alopecia associated with second-line anti-TB drugs in the global adverse drug reaction database, as of July 25, 2017, were submitted from Eritrea. It is wondering why this much variation is happening and this study is therefore aimed at quantifying the risk, identifying possible risk factors and elucidating the causal association between alopecia and the second-line anti-TB drugs in Eritrea. Methods This was a retrospective cohort study that included all patients with multi-drug resistant tuberculosis (MDR-TB) in Eritrea enrolled to Merhano MDR-TB referral hospital for treatment between June 2011 and December 2016. Results A total of 152 eligible MDR-TB patients on treatment were identified with a median observation time of 23 months. Historical longitudinal data of these patients was screened and found 35 cases of alopecia, possibly associated with MDR-TB treatment, with an incidence rate of about 13 cases per 1000 person-months. Majority of the cases (68.6%) developed alopecia after 18 months of exposure to MDR-TB treatment. Patients exposed to treatment for longer period of time (>23 months) were more likely to develop alopecia compared to those exposed for shorter time (p=0.001). Patients younger than 45 years of age reported higher rates of alopecia compared to the older age groups (adjusted OR=9.4; 95%CI: 2.41-36.86, p=0.001). Females were also more likely to develop alopecia compared to males (adjusted OR=3; 95%CI: 1.24 - 7.34, p=0.015). Conclusion Alopecia associated with MDR-TB treatment is frequent but its delayed time to onset might be a reason to be missed by several similar studies conducted elsewhere. Even though alopecia is not life-threatening and does not cause physical pain, the cosmetic effects of hair loss can be psychologically devastating.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
二线抗结核药物与脱发风险:一项回顾性队列研究
背景:脱发并不是二线抗结核药物的一个众所周知的不良反应。然而,厄立特里亚经常报道,截至2017年7月25日,全球药物不良反应数据库中83%的与二线抗结核药物相关的脱发报告来自厄立特里亚。令人好奇的是,为什么会发生如此大的差异,因此,这项研究旨在量化风险,确定可能的风险因素,并阐明厄立特里亚脱发与二线抗结核药物之间的因果关系。方法回顾性队列研究,纳入2011年6月至2016年12月在厄立特里亚Merhano耐多药结核病转诊医院就诊的所有耐多药结核病患者。结果共有152例符合条件的耐多药结核病患者接受治疗,平均观察时间为23个月。对这些患者的历史纵向资料进行了筛选,发现35例脱发,可能与耐多药结核病治疗有关,发病率约为每1000人月13例。大多数病例(68.6%)在接受耐多药结核病治疗18个月后出现脱发。与接受治疗时间较短的患者相比,接受治疗时间较长(>23个月)的患者更容易发生脱发(p=0.001)。年龄小于45岁的患者报告的脱发率高于年龄较大的患者(调整后OR=9.4;95%CI: 2.41 ~ 36.86, p=0.001)。与男性相比,女性患脱发的可能性也更大(调整后OR=3;95%CI: 1.24 ~ 7.34, p=0.015)。结论与耐多药结核病治疗相关的脱发是常见的,但其发病时间的延迟可能是其他地方进行的一些类似研究错过的一个原因。尽管脱发不会危及生命,也不会造成身体上的疼痛,但脱发对美容的影响可能会在心理上造成毁灭性的打击。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antidepressant: An Overview Quantification of 3?-Acetyl-11-Keto-?-Boswellic Acid and 11-Keto-?Boswellic Acid in the Resin of Boswellia species by HPTLC The Use of 3D Models to Test Potential Anti-SARS-CoV-2 Drugs and Infection Mechanisms Local Drug Delivery in Periodontal Therapy: A Contemporary Review Challenges of Hepatotoxicity Associated with Isoniazid Preventive Therapy among People Living with HIV in Eritrea
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1